Skip to main content

Commercialising cardiac autonomic modulation to treat Atrial Fibrillation

Project description

Novel treatment targets the origin of atrial fibrillation

Atrial fibrillation is a type of heart arrhythmia when rapid heart rate caused by chaotic electrical impulses in the atria result in rapid, uncoordinated contractions. This is a life-threatening condition with serious complications, such as stroke, and high worldwide prevalence. The most effective currently available treatment is cardiac ablation that specifically destroys heart tissue that triggers abnormal rhythm. However, this treatment requires highly trained personnel and carries significant risk of complications. AtriAN Medical has developed a novel treatment to target specifically the origin of the signal that causes atrial fibrillation and prevents the arrhythmia. This treatment promises high success rates and reduced risk of complications. The current EU-funded Neuron-AFib project will finalise testing and validation of the technology in order to meet regulatory requirements, followed by a safety and treatment efficacy clinical trial with broad patient enrolment.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-2

Coordinator

ATRIAN MEDICAL LIMITED
Net EU contribution
€ 2 348 941,00
Address
Unit 204 Nuig Business Innovation Centre Upper Newcastle
H91W60E Galway
Ireland

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 1 009 264,00